Moderna Therapeutics is having quite a year, and the Cambridge, MA, biotech just put a $110 million capstone on 2013, raising a colossal new round and riding high on technology that promises to transform the human body into a drug factory.
Moderna Therapeutics' messenger RNA therapy platform is attracting attention these days. The Cambridge, MA-based company has won a notable deal with the U.S. government--worth up to $25 million--to develop its therapeutics to make antibody-producing drugs that would combat emerging infectious diseases and biological health threats.
Our annual Fierce 15 report on a top class of up-and-coming private biotechs came out today and I wanted to highlight the responses from many of the companies which are on the list. Read more | Check out this year's report
Last year when Ryan McBride and I were sorting through our short list of candidates, we both felt that Seaside Therapeutics deserved a spot on the list. The small company had raised a considerable...
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...
Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in the Boston area and The Netherlands, he told FierceBiotech in an interview. Read more >>
The biotech, which struck a major development deal with AstraZeneca just months after it shed stealth status, has landed former Genzyme CEO Henri Termeer for the board of directors.
AstraZeneca today had another big round of dismal revenue numbers to explain today. With generic rivals tearing at some of its key franchises, the pharma giant reported a 13% drop in revenue for the first quarter.
The dust hasn't settled from the massive layoffs and R&D consolidation announced over at AstraZeneca last week, but analysts have begun to piece together what the major changes mean for the beleaguered pharma giant.
AstraZeneca's new CEO Pascal Soriot has wrapped his review of the Big Pharma company and followed up deep cuts in a global reorganization of the R&D side with a pair of new research initiatives while bringing out the budget ax to chop off another adding 2,300 sales and administration jobs in the struggling business.